A novel testing service to rapidly identify stroke patients not responding to Clopidogrel antithrombotic therapy, and switch them to alternative effective medication. (Platelet Solutions-RPFT).

血小板解决方案有限公司(PS Ltd.)是一家建立在诺丁汉大学心血管医学广泛研究和经验基础上的微型中小企业。当大脑中的血液流动中断时，就会发生中风；要么是由于血栓、缺血性中风(IS)，要么是由于动脉破裂(出血性中风)。在英国，每3分钟就会发生一次S，所有年龄段的人都会受到打击--在英国，每年有90.1K国际空间站和46K短暂性脑缺血发作(TIA或微型中风，症状在24小时内消失)。2009年，中风护理的年度总成本估计为9b GB--占英国NHS总成本的5%--直接护理成本为4.5b GB，非正式护理成本为2.4b GB，间接成本为2.1b GB。在首次中风后的5年内，约有25%的风险会再次发生更令人衰弱的事件。为了减少再次中风的风险，所有患者在IS和TIA后终生接受氯吡格雷抗血小板治疗。然而，并不是所有的患者对药物治疗都有反应，也没有进行任何测试来确定他们是否会使这一组患者再次中风的风险更高。我们已经开发了一种商业和技术创新的测试服务，以确定哪些患者没有受益于氯吡格雷药物治疗，而广泛可用的替代疗法(阿司匹林和潘生丁)将对他们有利。我们预计，完全采用这项服务可以为NHS每年节省高达3850万英镑的直接医疗费用，为英国经济每年节省7910万英镑。在非正式护理和生产力方面的损失。该项目的成功将使普莱特解决方案有限公司转变为中小企业。

PLATELET SOLUTIONS LTD (PS Ltd.) is a micro-SME founded on extensive research andexperience in Cardiovascular Medicine at Nottingham University. A stroke occurs whenblood flow in the brain is interrupted; either due to blood clots, ischaemic stroke (IS), or anartery bursts (haemorrhagic stroke). One occurs every 3 mins 27 s in the UK striking peopleof all ages - each year in the UK there are 90.1k ISs, and 46k transient ischaemic attacks(TIAs or mini-strokes, where symptoms resolve in 24 hrs). In 2009 the total annual costs ofstroke care were estimated at £9b - 5% of total UK NHS costs - direct care of £4.5b, informalcare £2.4b, and indirect costs of £2.1b. Within 5 years of the first stroke there is a ca. 25% riskof recurrence of a more debilitating event. To reduce the risk of another stroke all patientsafter IS and TIA receive antiplatelet treatment with clopidogrel for life. However, not allpatients respond to the drug therapy and no testing is performed to identify them placing thissub-group at higher risk of another stroke. We have developed a commercially and technologyinnovative testing service to identify patients who are not benefiting from clopidogrel drugtherapy and for whom widely available alternative therapy (aspirin with dipyridamole) wouldbe beneficial. We project that full uptake of the service could save the NHS up to £38.5m p.a.in direct medical costs, and the UK economy £79.1m p.a. in informal care and productivityloses. Success of the project will transform Platelet Solutions Ltd. to a SME.